New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.
Oct 10, 2010